Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignanciesAmita Patnaik, Eric K Rowinsky, Miguel A Villalona, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitorLisa J Green, Philip Marder, Chad Ray, et al.
Molecular Cancer Therapeutics|July 5, 2012
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinibOndrej Kalous, Dylan Conklin, Amrita J Desai, et al.
Investigational New Drugs|March 12, 2017
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancersJennifer R Diamond, Barbara Goff, Martin D Forster, et al.
Anti-Cancer Drugs|November 29, 2007
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumorsD Ross Camidge, S Gail Eckhardt, Lia Gore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2017
A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid TumorsCarolyn D Britten, Elizabeth Garrett-Mayer, Steven H Chin, et al.
Targeted Oncology|October 26, 2017
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced CancerZev A Wainberg, Maria Alsina, Heloisa P Soares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumorsPasi A Jänne, David S Boss, D Ross Camidge, et al.
Investigational New Drugs|June 11, 2003
Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeksAlison J Davis, Karen A Gelmon, Lillian L Siu, et al.
Investigational New Drugs|July 13, 2019
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinomaMarcus Noel, Eileen M O'Reilly, Brian M Wolpin, et al.
Pageof 4